2023
Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand
Brooks J, Montgomery A, Dalbeth N, Sapsford M, Kee R, Cooper A, Quincey V, Bhana S, Gore-Massy M, Hausmann J, Liew J, Machado P, Sufka P, Sirotich E, Robinson P, Wallace Z, Yazdany J, Grainger R. Omicron variant infection in inflammatory rheumatological conditions – outcomes from a COVID-19 naive population in Aotearoa New Zealand. The Lancet Regional Health - Western Pacific 2023, 38: 100843. PMID: 37520279, PMCID: PMC10372177, DOI: 10.1016/j.lanwpc.2023.100843.Peer-Reviewed Original ResearchInflammatory rheumatic diseasesSARS-CoV-2 infectionHospitalisation/deathOmicron variant infectionConnective tissue diseaseRheumatic diseasesVariant infectionCOVID-19SARS-CoV-2 Omicron variantSingle vaccine doseCOVID-19 hospitalisationMultivariable adjusted modelsCOVID-19 vaccination statusMultivariable logistic regressionCOVID-19 vaccinationHigh vaccination ratesRituximab useVaccine doseInflammatory arthritisVaccination statusClinical factorsTissue diseaseDisease characteristicsVaccination ratesRisk factors
2021
Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study
Siddiqi ZA, Nowak RJ, Mozaffar T, O'Brien F, Yountz M, Patti F, Mazia C, Wilken M, Wilken M, Barroso F, Saba J, Rugiero M, Bettini M, Chaves M, Vidal G, Garcia A, De Bleecker J, Van den Abeele G, Koning K, De Mey K, Mercelis R, Mahieu D, Wagemaekers L, Van Damme P, Depreitere A, Schotte C, Smetcoren C, Stevens O, Van Daele S, Vandenbussche N, Vanhee A, Verjans S, Vynckier J, D'Hont A, Tilkin P, Siqueira Carvalho A, Brockhausen I, Feder D, Ambrosio D, César P, Melo A, Ribeiro R, Rocha R, Rosa B, Veiga T, Silva L, Engel M, Geraldo J, Penha Ananias Morita M, Coelho E, Paiva G, Pozo M, Prando N, Torres D, Butinhao C, Duran G, Fialho T, Silva T, Gonçalves L, Pazetto L, Volpe L, Duca L, Friedrich M, Guerreiro A, Mohr H, Martins M, Cruz Pacheco D, Ferreira L, Macagnan A, Pinto G, Cassia Santos A, Oliveira A, Andrade A, Annes M, Silva L, Lino V, Pinto W, Assis N, Carrara F, Miranda C, Souza I, Fernandes P, Phan C, Narayan J, Blackmore D, Mallon A, Roderus R, Watt E, Vohanka S, Bednarik J, Chmelikova M, Cierny M, Toncrova S, Junkerova J, Kurkova B, Reguliova K, Zapletalova O, Pitha J, Novakova I, Tyblova M, Jurajdova I, Wolfova M, Andersen H, Harbo T, Vinge L, Krogh S, Mogensen A, Vissing J, Højgaard J, Witting N, Autzen A, Pedersen J, Erälinna J, Laaksonen M, Oksaranta O, Harrison T, Eriksson J, Rozsa C, Horvath M, Lovas G, Matolcsi J, Szabo G, Jakab G, Szabadosne B, Vecsei L, Dezsi L, Varga E, Konyane M, Antonini G, Di Pasquale A, Garibaldi M, Morino S, Troili F, Fionda L, Di Pasquale A, Garibaldi M, Saccà F, Filla A, Costabile T, Marano E, Fasanaro A, Marsili A, Puorro G, Mantegazza R, Antozzi C, Bonanno S, Camera G, Locatelli A, Maggi L, Pasanisi M, Campanella A, Evoli A, Alboini P, D'Amato V, Iorio R, Inghilleri M, Fionda L, Frasca V, Giacomelli E, Gori M, Lopergolo D, Onesti E, Frasca V, Gabriele M, Uzawa A, Kanai T, Kawaguchi N, Mori M, Kaneko Y, Kanzaki A, Kobayashi E, Murai H, Masaki K, Matsuse D, Matsushita T, Uehara T, Shimpo M, Jingu M, Kikutake K, Nakamura Y, Sano Y, Utsugisawa K, Nagane Y, Kamegamori I, Tsuda T, Fujii Y, Futono K, Ozawa Y, Mizugami A, Saito Y, Samukawa M, Suzuki H, Morikawa M, Kamakura S, Miyawaki E, Shiraishi H, Miyazaki T, Motomura M, Mukaino A, Yoshimura S, Asada S, Yoshida S, Amamoto S, Kobashikawa T, Koga M, Maeda Y, Takada K, Takada M, Tsurumaru M, Yamashita Y, Yoshida S, Suzuki Y, Akiyama T, Narikawa K, Tano O, Tsukita K, Kurihara R, Meguro F, Fukuda Y, Sato M, Okumura M, Funaka S, Kawamura T, Nakamori M, Takahashi M, Taichi N, Hasuike T, Higuchi E, Kobayashi H, Osakada K, Imai T, Tsuda E, Shimohama S, Hayashi T, Hisahara S, Imai T, Kawamata J, Murahara T, Saitoh M, Shimohama S, Suzuki S, Yamamoto D, Ishiyama Y, Ishiyama N, Noshiro M, Takeyama R, Uwasa K, Yasuda I, Kim B, Lee C, Koo Y, Seok H, Kang H, Ra H, Kim B, Cho E, Choi M, Lee H, Min J, Seok J, Lee J, Koh D, Kwon J, Park S, Choi E, Hong Y, Ahn S, Koo D, Lim J, Shin C, Hwang J, Kim M, Kim S, Jeong H, Jung J, Kim Y, Lee H, Shin H, Hwang E, Shin M, Kooi A, Visser M, Gibson T, Casasnovas C, Aguilo M, Homedes‐Pedret C, Palacios N, Porras L, Santamaria V, Lazaro A, Tejedor E, Salcedo P, Fernandez‐Fournier M, Ruiz P, Rivera F, Fernandez‐Fournier M, Sastre M, Carbonell J, Sune P, Figueras M, Gili G, Mazuela G, Illa I, Vicente E, Diaz‐Manera J, Gutiérrez L, Garcia R, Vidal N, Arribas‐Ibar E, Piehl F, Hietala A, Bjarbo L, Sengun I, Meherremova A, Ozcelik P, Balkan B, Tuga C, Ugur M, Erdem‐Ozdamar S, Bekircan‐Kurt C, Acar N, Yilmaz E, Caliskan Y, Orsel G, Efendi H, Aydinlik S, Cavus H, Kutlu A, Becerikli G, Semiz C, Tun O, Terzi M, Dogan B, Onar M, Sen S, Cavdar T, Veske A, Norwood F, Dimitriou A, Gollogly J, Mahdi‐Rogers M, Seddigh A, Sokratous G, Maier G, Sohail F, Jacob S, Sadalage G, Torane P, Brown C, Shah A, Sathasivam S, Arndt H, Davies D, Watling D, Amato A, Cochrane T, Salajegheh M, Roe K, Amato K, Toska S, Wolfe G, Silvestri N, Patrick K, Zakalik K, Katz J, Miller R, Engel M, Forshew D, Bravver E, Brooks B, Sanjak M, Plevka S, Burdette M, Cunningham S, Sanjak M, Kramer M, Nemeth J, Schommer C, Scott T, Juel V, Guptill J, Hobson‐Webb L, Massey J, Beck K, Carnes D, Loor J, Anderson A, Pascuzzi R, Bodkin C, Kincaid J, Snook R, Guingrich S, Micheels A, Chaudhry V, Corse A, Mosmiller B, Kelley A, Ho D, Srinivasan J, Vytopil M, Jara J, Ventura N, Carter C, Donahue C, Herbert C, Scala S, Weiner E, Alam S, McKinnon J, Haar L, McKinnon N, Alcon K, McKenna K, Sattar N, Daniels K, Jeffery D, Freimer M, Hoyle J, Kissel J, Agriesti J, Chelnick S, Mezache L, Pineda C, Muharrem F, Karam C, Khoury J, Marburger T, Kaur H, Dimitrova D, Gilchrist J, Agrawal B, Elsayed M, Kohlrus S, Ardoin A, Darnell T, Golden L, Lokaitis B, Seelbach J, Muppidi S, Goyal N, Sakamuri S, So Y, Paulose S, Pol S, Welsh L, Bhavaraju‐Sanka R, Gonzalez A, Dishman L, Jones F, Gonzalez A, Padilla P, Saklad A, Silva M, Nations S, Trivedi J, Hopkins S, Kazamel M, Alsharabati M, Lu L, Nozaki K, Mumfrey‐Thomas S, Woodall A, Cash T, Goyal N, Roy G, Mathew V, Maqsood F, Minton B, Jones H, Rosenfeld J, Garcia R, Echevarria L, Garcia S, Pulley M, Aranke S, Berger A, Shah J, Shabbir Y, Smith L, Varghese M, Shabbir Y, Gutmann L, Gutmann L, Jerath N, Nance C, Swenson A, Olalde H, Kressin N, Sieren J, Barohn R, Dimachkie M, Glenn M, McVey A, Pasnoor M, Statland J, Wang Y, Liu T, Emmons K, Jenci N, Locheke J, Fondaw A, Johns K, Rico G, Walsh M, Herbelin L, Hafer‐Macko C, Kwan J, Zilliox L, Callison K, Young V, DiSanzo B, Naunton K, Benatar M, Bilsker M, Sharma K, Cooley A, Reyes E, Michon S, Sheldon D, Steele J, Howard J, Karam C, Traub R, Chopra M, Vu T, Katzin L, McClain T, Harvey B, Hart A, Huynh K, Beydoun S, Chilingaryan A, Doan V, Droker B, Gong H, Karimi S, Lin F, McClain T, Polaka K, Shah A, Tran A, Akhter S, Malekniazi A, Tandan R, Hehir M, Waheed W, Lucy S, Weiss M, Distad J, Strom S, Downing S, Kim B, Bertorini T, Arnold T, Henderson K, Pillai R, Liu Y, Wheeler L, Hewlett J, Vanderhook M, Dicapua D, Keung B, Kumar A, Patwa H, Robeson K, Yang I, Nye J, Vu H. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle & Nerve 2021, 64: 662-669. PMID: 34590717, DOI: 10.1002/mus.27422.Peer-Reviewed Original ResearchConceptsRituximab useMyasthenia gravisSubgroup analysisAmerica Post-Intervention StatusMyasthenia Gravis ActivitiesSafety of eculizumabOpen-label extensionMyasthenia Gravis FoundationUnmet treatment needDaily living (IADL) total scorePost-intervention statusEculizumab treatmentWeek 130Rituximab treatmentBaseline characteristicsMost patientsPersistent symptomsSafety profileEffective therapyTreatment needsEculizumabMinimal manifestationsExtension studyREGAIN studyPatients
2020
Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Goshua G, Sinha P, Hendrickson J, Tormey C, Bendapudi P, Lee A. Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood 2020, 136: 18-19. DOI: 10.1182/blood-2020-138515.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioThrombotic thrombocytopenic purpuraQuality-adjusted life yearsIntensive care unitTherapeutic plasma exchangeHERCULES trialCost-effectiveness analysisCaplacizumab treatmentRituximab useTITAN trialHospital lengthTPE sessionsThrombocytopenic purpuraTreatment armsAcquired Thrombotic Thrombocytopenic PurpuraLong-term disease courseThrombotic microangiopathy leadingEnd-organ damagePlatelet count recoveryLong-term followHealth system perspectiveOne-way sensitivity analysesPotential confounding factorsCost-effectiveness ratioLife-threatening diseaseCost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Goshua G, Gokhale A, Hendrickson JE, Tormey C, Lee AI. Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances 2020, 4: 539-545. PMID: 32045473, PMCID: PMC7013262, DOI: 10.1182/bloodadvances.2019000827.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraTherapeutic plasma exchangeRituximab useAdmission dayThrombocytopenic purpuraTPE proceduresInpatient settingAutoimmune thrombotic thrombocytopenic purpuraCost of rituximabDisease flareLifelong threatPlasma exchangeHematologic emergencyInpatient costsRelapse riskSevere autoimmuneRituximabAcademic centersCost savingsHospitalPurpuraPatientsAdmissionCohortSetting
2009
Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)
Rao V, Price S, Perkins K, Aldridge P, Tretler J, Davis J, Dale J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Newburger P, Puck J, Fleisher T. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatric Blood & Cancer 2009, 52: 847-852. PMID: 19214977, PMCID: PMC2774763, DOI: 10.1002/pbc.21965.Peer-Reviewed Original ResearchConceptsAutoimmune lymphoproliferative syndromeAutoimmune hemolytic anemiaRefractory immune thrombocytopeniaMedian response durationUse of rituximabDisorder of apoptosisMarked lymphadenopathyProlonged neutropeniaRituximab infusionRituximab useSurgical splenectomyALPS patientsImmune thrombocytopeniaPalpable spleenRituximab therapySignificant splenomegalyPolysaccharide vaccineAutoimmune destructionMedication optionsMultilineage cytopeniasRefractory cytopeniaAutoreactive lymphocytesAsplenic individualsAntibody responseLymphoproliferative syndrome
2007
Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS).
Dale J, Price S, Tretler J, Aldridge P, Montague S, Davis J, Gill F, Hartman K, Stork L, Gnarra D, Krishnamurti L, Puck J, Fleisher T, Rao V. Use of Rituximab for Refractory Immune Cytopenias Associated with Autoimmune Lymphoproliferative Syndrome (ALPS). Blood 2007, 110: 1319. DOI: 10.1182/blood.v110.11.1319.1319.Peer-Reviewed Original ResearchAutoimmune lymphoproliferative syndromeALPS patientsMycophenolate mofetilRituximab therapyDouble-negative T lymphocytesALPS phenotypeNegative T lymphocytesUse of rituximabCompletion of therapyRed cell transfusionAdult male patientsNIH Clinical CenterLong-term riskDurable normalizationPneumococcal sepsisPrednisone pulsesRefractory ITPRituximab infusionRituximab useWeekly vincristineCell transfusionHepatitis CImmune thrombocytopeniaPalpable spleenPolysaccharide vaccine
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply